Fortress Biotech, Inc.

FBIO • Biotechnology

$2.72

▲ +0.01 (+0.37%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$86.47M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Márgenes estables o en mejora · 10.8%Múltiplo de ganancias razonable · 14.98Liquidez saludable · 2.49Tendencia de crecimiento negativa

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 14 ago 2026, 12:26 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.72

Change0.37%

Shares Out31.79M

Market Cap$86.47M

Enterprise Value$-56.79M

52W Range1.97 - 4.53

Beta1.21

P/E0.79

P/S1.28

P/B0.53

P/FCF0.47

EV/Sales-0.84

Price$2.72

Change0.37%

Shares Out31.79M

Market Cap$86.47M

Enterprise Value$-56.79M

52W Range1.97 - 4.53

Beta1.21

P/E0.79

P/S1.28

P/B0.53

P/FCF0.47

EV/Sales-0.84

EV/EBITDA8.15

EV/FCF-0.31

Earnings Yield126.99%

FCF Yield214.17%

Dividend Yield0.44%

Gross Margin66.92%

Oper. Margin-111.00%

Profit Margin10.77%

Debt/Eq1.49

Current Ratio2.49

Quick Ratio2.30

Target$5.00

Target Upside83.82%

Target Median$5.00

Target Range5.00 - 5.00

Volume1.39M

Avg Volume510.07K

EPS Surprise3.04

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

57/100

Fortaleza financiera

Deuda, caja, estabilidad

63/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

85/100

Por qué este puntaje▼

Márgenes estables o en mejora · 10.8%Múltiplo de ganancias razonable · 14.98Liquidez saludable · 2.49Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

FBIO

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-14

Bajo

$5.00

Promedio

$5.00

Mediana

$5.00

Alto

$5.00

Resumen de la compañía

IPO: 11/17/2011

Industria: Biotechnology

P/B i: 0.53

Deuda / Patrimonio i: 1.49

Margen operativo: -111.00%

Margen neto: 10.77%

ROE i: -

ROIC: -

Salud financiera

Puntaje13 / 20

Deuda / Patrimonio: 1.49

Ratio corriente: 2.49

Ratio rápido: 2.30

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Jin David

Transacción: 06/22/2026

COMPRA

Cambio

+400,000

Precio

Not reported

Presentación

06/24/2026

Tipo

COMPRA

Jin David

Transacción: 04/01/2026

COMPRA

Cambio

+2,967

Precio

$2.18

Presentación

04/01/2026

Tipo

COMPRA

WEISS MICHAEL S

Transacción: 03/18/2026

COMPRA

Cambio

+475,424

Precio

Not reported

Presentación

03/20/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Jin David	COMPRA	+400,000	Not reported	06/22/2026	06/24/2026
Jin David	COMPRA	+2,967	$2.18	04/01/2026	04/01/2026
WEISS MICHAEL S	COMPRA	+475,424	Not reported	03/18/2026	03/20/2026
ROSENWALD LINDSAY A MD	COMPRA	+475,424	Not reported	03/18/2026	03/20/2026
LOBELL J JAY	COMPRA	+27,322	Not reported	01/01/2026	01/05/2026
Hoenlein Malcolm	COMPRA	+27,322	Not reported	01/01/2026	01/05/2026
Lorenz Kevin	COMPRA	+27,322	Not reported	01/01/2026	01/05/2026
Harvey Jimmie	COMPRA	+27,322	Not reported	01/01/2026	01/05/2026
Klein Dov	COMPRA	+27,322	Not reported	01/01/2026	01/05/2026
Jin David	COMPRA	+2,711	$1.31	10/01/2025	10/02/2025
Jin David	COMPRA	+5,000	$1.22	04/01/2025	04/01/2025
ROSENWALD LINDSAY A MD	COMPRA	+454,153	Not reported	01/01/2025	01/03/2025
WEISS MICHAEL S	COMPRA	+454,153	Not reported	01/01/2025	01/03/2025
Hoenlein Malcolm	COMPRA	+49,383	Not reported	01/01/2025	01/03/2025
Lorenz Kevin	COMPRA	+49,383	Not reported	01/01/2025	01/03/2025
Harvey Jimmie	COMPRA	+49,383	Not reported	01/01/2025	01/03/2025
Lu Lucy	COMPRA	+49,383	Not reported	01/01/2025	01/03/2025
Klein Dov	COMPRA	+49,383	Not reported	01/01/2025	01/03/2025
Jin David	COMPRA	+1,000,000	Not reported	12/19/2024	12/23/2024
Jin David	COMPRA	+2,625	$1.23	10/01/2024	10/01/2024

Sobre la compañía

Fortress Biotech, Inc.

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Fuente - Link

Competidores

ADAG CRVO GANX IMUX NTRB PMVP RLMD TCRX VXRT XBIT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO ® and UNLOXCYT ™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2026. Lindsay A.

GlobeNewsWire

Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript

Seeking Alpha

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)

NEW YORK, Aug. 7, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Fortress Biotech, Inc. (NASDAQ: FBIO) concerning possible breaches of fiduciary duties. If you are a current shareholder of FBIO, you can obtain additional information here: https://zlk.com/compensation2/fbio-information-request-form or contact Joseph E.

PRNewsWire

Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026.

GlobeNewsWire

Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, closed an oversubscribed $130 million Series B financing to support the late-stage global clinical development and commercialization preparation for dotinurad, a next-generation, once daily, oral URAT1 inhibitor for the treatment of gout. Dotinurad's clinical development program includes two ongoing Phase 3 registration-directed trials, RUBY and TOPAZ, as well as the ongoing Phase 2 AMETHYST study, collectively designed to evaluate dotinurad across a broad spectrum of patients with gout, including those with limited treatment options.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.22	2.82	3.04
2026-03-31	0.42	-0.21	-0.63
2025-11-14	-0.43	0.11	0.54
2025-08-14	-0.31	-0.46	-0.15
2025-05-21	-0.44	-1.03	-0.59
2025-03-27	-0.79	-0.53	0.26
2024-11-14	-0.27	-0.76	-0.49
2024-08-13	-1.32	-0.73	0.59
2024-05-15	-2.03	-1.03	1
2024-03-28	-1.97	-0.53	1.44
2023-11-14	-3.53	-0.94	2.59
2023-08-14	-3.9	-3.6	0.3